Omnicell (NASDAQ:OMCL) had its price objective hoisted by Wells Fargo & Co from $59.00 to $61.00 in a research report released on Monday morning. Wells Fargo & Co currently has a market perform rating on the stock.
Several other equities analysts have also recently commented on the stock. Oppenheimer raised their target price on shares of Omnicell from $71.00 to $73.00 and gave the company an outperform rating in a research note on Friday, October 26th. Cantor Fitzgerald reissued a buy rating and set a $63.00 target price on shares of Omnicell in a research note on Thursday, July 26th. BidaskClub cut shares of Omnicell from a strong-buy rating to a buy rating in a research note on Thursday, July 12th. Piper Jaffray Companies raised their target price on shares of Omnicell from $44.00 to $55.00 and gave the company a neutral rating in a research note on Friday, July 27th. Finally, TheStreet raised shares of Omnicell from a c+ rating to a b rating in a research note on Friday, July 27th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $69.86.
Shares of OMCL stock traded down $0.79 during trading hours on Monday, reaching $68.89. The stock had a trading volume of 6,064 shares, compared to its average volume of 399,417. The company has a quick ratio of 1.32, a current ratio of 1.78 and a debt-to-equity ratio of 0.27. Omnicell has a twelve month low of $39.75 and a twelve month high of $73.00. The stock has a market cap of $2.75 billion, a PE ratio of 384.22, a price-to-earnings-growth ratio of 4.36 and a beta of 0.98.
In other news, Director James T. Judson sold 5,000 shares of Omnicell stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $71.18, for a total value of $355,900.00. Following the transaction, the director now owns 29,952 shares of the company’s stock, valued at approximately $2,131,983.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dan S. Johnston sold 6,250 shares of Omnicell stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $63.47, for a total transaction of $396,687.50. Following the completion of the transaction, the executive vice president now directly owns 35,996 shares in the company, valued at approximately $2,284,666.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,277 shares of company stock worth $1,654,248. 3.71% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Omnicell in the 2nd quarter worth approximately $102,000. Virtu Financial LLC acquired a new position in shares of Omnicell in the 2nd quarter worth approximately $204,000. Everence Capital Management Inc. acquired a new position in shares of Omnicell in the 3rd quarter worth approximately $204,000. First Republic Investment Management Inc. acquired a new position in shares of Omnicell in the 2nd quarter worth approximately $226,000. Finally, Jane Street Group LLC acquired a new position in shares of Omnicell in the 1st quarter worth approximately $237,000. 98.80% of the stock is currently owned by institutional investors.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.